Help Navigate Common Hurdles With GLP-1 Agonists
February 2024
Questions are rolling in about GLP-1 agonists...dulaglutide (Trulicity), liraglutide (Victoza), semaglutide (Ozempic,etc), etc.
It’s partly because these meds are a first-line option for type 2 diabetes with compelling indications...such as CV or kidney disease.
Plus semaglutide or the dual agonist tirzepatide (Zepbound,etc) seem to be the most effective meds for managing overweight or obesity.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote